制酸剤の世界市場

制酸剤の世界市場は2030年までに79億米ドルに達する見込み

2023年に68億米ドルと推定される制酸剤の世界市場は、2023～2030年の分析期間においてCAGR 2.2%で成長し、2030年には79億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるプロトンポンプ阻害剤は、CAGR 3.7%を記録し、分析期間終了時には22億米ドルに達すると予測されます。H2拮抗薬セグメントの成長率は、分析期間中CAGR 2.5%と推定されます。

米国市場は18億米ドルと推定、中国はCAGR 4.8%で成長予測

米国の制酸剤市場は2023年に18億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに16億米ドルの市場規模に達すると予測され、分析期間2023-2030年のCAGRは4.8%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ0.5％と1.6％と予測されています。欧州では、ドイツがCAGR 1.1%で成長すると予測されています。

世界の制酸剤市場- 主要動向と促進要因のまとめ

制酸剤は、胃酸を中和し、胸やけ、酸逆流、胃食道逆流症（GERD）の症状を緩和するために使用される市販薬です。胃のpH値を上昇させることで胃酸を抑え、消化不良や胃酸過多に伴う不快感を緩和します。制酸剤に含まれる一般的な成分には、水酸化マグネシウム、水酸化アルミニウム、炭酸カルシウム、炭酸水素ナトリウムなどがあります。これらの化合物の働きはそれぞれ微妙に異なりますが、酸の中和という基本的な機能はすべて同じです。制酸剤は、錠剤、カプセル、液体、粉末など様々な形態で販売されており、消費者にとって多用途で便利な製品となっています。制酸剤は、胃の不快感に対する最初の防衛線となることが多く、その迅速な作用と入手のしやすさから人気があります。

制酸剤の市場は、医薬製剤の進歩により、これらの製品の有効性と使用感が向上し、時代とともに進化してきました。最近の動向としては、制酸剤とアルギン酸の組み合わせがあり、これは胃酸を中和するだけでなく、酸が食道に逆流するのを防ぐ物理的なバリアを形成します。また、ショウガ、ウコン、カンゾウの根などのハーブ成分を使用したナチュラルでオーガニックな制酸剤の動向も高まっており、より優しい選択肢を求める健康志向の消費者にアピールしています。さらに、メーカーは制酸剤製品の風味やテクスチャーの改善に注力しています。こうした改良は、製品をより嗜好性が高く、摂取しやすくするためのもので、高齢の患者など、従来の製剤では摂取が困難な患者にとって特に重要です。

制酸剤市場の成長は、世界人口の胃腸障害の増加、ライフスタイルの変化、消化器系健康のための市販薬に対する消費者の認識向上など、いくつかの要因によってもたらされます。辛い食べ物、カフェイン、アルコールの大量摂取を含む食習慣は、酸味と胸焼けの蔓延に寄与し、制酸剤製品の需要を煽っています。加えて、加齢に伴う生理的変化により消化器系の問題を抱えやすい高齢者人口の増加も、この市場の拡大に寄与しています。消費者の行動はセルフメディケーションや予防的健康管理にシフトしており、制酸剤の売上をさらに押し上げています。さらに、迅速な緩和と少ない副作用を提供する製品処方の革新、積極的なマーケティング戦略、幅広い流通チャネルにより、制酸剤は消費者の間で非常に身近な存在となり、人気が高まっています。市販の制酸剤に対する規制上の支援も、その安全性と有効性を確保し、消費者の信頼を維持し、市場の成長を促進する上で重要な役割を果たしています。これらの要因が相まって、消費者のニーズや健康動向の変化に対応し、成長を続ける強固な市場が形成されています。

調査対象企業の例（全54件）

• AdvaCare Pharma
• Alkem Laboratories Ltd.
• Bayer AG
• Bhumi Pharmaceuticals
• Cipla Inc
• Haleon Plc
• GCP Laboratories
• Mylanta（A brand of McNeil Consumer Pharmaceuticals Company）
• Nestle New Zealand Ltd.
• Novartis AG
• Pfizer Inc
• Reckitt Benckiser Group PLC
• Rolaids（A brand of Procter & Gamble）
• SPI Pharma
• Tums（A brand of Haleon）
• ;

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Antacids Market to Reach US$7.9 Billion by 2030

The global market for Antacids estimated at US$6.8 Billion in the year 2023, is expected to reach US$7.9 Billion by 2030, growing at a CAGR of 2.2% over the analysis period 2023-2030. Proton Pump Inhibitors, one of the segments analyzed in the report, is expected to record a 3.7% CAGR and reach US$2.2 Billion by the end of the analysis period. Growth in the H2 Antagonist segment is estimated at 2.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.8 Billion While China is Forecast to Grow at 4.8% CAGR

The Antacids market in the U.S. is estimated at US$1.8 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$1.6 Billion by the year 2030 trailing a CAGR of 4.8% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 0.5% and 1.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.1% CAGR.

Global Antacids Market - Key Trends and Drivers Summarized

Antacids are over-the-counter medications used to neutralize stomach acid and relieve symptoms of heartburn, acid reflux, and gastroesophageal reflux disease (GERD). They work by raising the pH level in the stomach, thereby reducing the acidity and alleviating the discomfort associated with indigestion and sour stomach. Common ingredients in antacids include magnesium hydroxide, aluminum hydroxide, calcium carbonate, and sodium bicarbonate. Each of these compounds works slightly differently, but all serve the same basic function of acid neutralization. Antacids are available in various forms, including tablets, capsules, liquids, and powders, making them versatile and convenient for consumers to use. They are often the first line of defense against occasional stomach discomfort and are popular due to their rapid action and availability.

The market for antacids has evolved over time with advances in pharmaceutical formulations enhancing the effectiveness and user experience of these products. Recent developments include the combination of antacids with alginate, which not only neutralizes stomach acid but also forms a physical barrier that prevents acid from rising back into the esophagus. There is also a growing trend towards natural and organic antacid alternatives that use herbal ingredients such as ginger, turmeric, and licorice root, which appeal to health-conscious consumers looking for gentler options. Additionally, manufacturers have been focusing on improving the flavor and texture of antacid products, which can often be a barrier to compliance for many users. These improvements are designed to make products more palatable and easier to ingest, which is particularly important for elderly patients and others who may have difficulties with conventional formulations.

The growth in the antacids market is driven by several factors, including an increase in gastrointestinal disorders among the global population, lifestyle changes, and enhanced consumer awareness of over-the-counter remedies for digestive health. Dietary habits that include high consumption of spicy foods, caffeine, and alcohol contribute to the prevalence of acidity and heartburn, fueling demand for antacid products. Additionally, the growing elderly population, which is more prone to digestive issues due to physiological changes with aging, also contributes to the expansion of this market. Consumer behavior has shifted towards self-medication and preventive health management, further bolstering the sales of antacids. Furthermore, innovations in product formulations that offer faster relief and fewer side effects, along with aggressive marketing strategies and broad distribution channels, have made antacids highly accessible and popular among consumers. Regulatory support for over-the-counter antacid products also plays a crucial role in ensuring their safety and efficacy, maintaining consumer trust and driving market growth. Together, these factors depict a robust market that continues to adapt and thrive in response to changing consumer needs and health trends.

Select Competitors (Total 54 Featured) -

• AdvaCare Pharma
• Alkem Laboratories Ltd.
• Bayer AG
• Bhumi Pharmaceuticals
• Cipla Inc
• Haleon Plc
• GCP Laboratories
• Mylanta (A brand of McNeil Consumer Pharmaceuticals Company)
• Nestle New Zealand Ltd.
• Novartis AG
• Pfizer Inc
• Reckitt Benckiser Group PLC
• Rolaids (A brand of Procter & Gamble)
• SPI Pharma
• Tums (A brand of Haleon)
• ;

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Global Economic Update
  • Antacids - Global Key Competitors Percentage Market Share in 2024 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Global Increase in Gastrointestinal Disorders Drives Demand for Antacids
  • Lifestyle Changes and Dietary Habits Propel Antacid Consumption
  • Over-the-Counter Availability Expands Addressable Market for Antacids
  • Innovations in Drug Formulations Strengthen the Business Case for Advanced Antacids
  • Rising Health Consciousness Spurs Consumer Demand for Natural and Organic Antacids
  • E-commerce Growth Accelerates Market Access and Adoption of Antacids
  • Aging Population Globally Drives Antacid Usage Due to Increased Acid Reflux Incidents
  • Flavored Antacid Variants Propel Popularity and Consumer Acceptance
  • Increasing Incidences of Stress-Related Gastric Issues Drive Antacid Demand
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Antacids Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Antacids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Antacids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 4: World 16-Year Perspective for Antacids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Proton Pump Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Proton Pump Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 7: World 16-Year Perspective for Proton Pump Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for H2 Antagonist by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 9: World Historic Review for H2 Antagonist by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 10: World 16-Year Perspective for H2 Antagonist by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Acid Neutralizers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Acid Neutralizers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 13: World 16-Year Perspective for Acid Neutralizers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Anti-H.Pyrolic Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Anti-H.Pyrolic Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 16: World 16-Year Perspective for Anti-H.Pyrolic Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 19: World 16-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Injectables Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Injectables Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 22: World 16-Year Perspective for Injectables Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Oral Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Oral Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 25: World 16-Year Perspective for Oral Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 28: World 16-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 31: World 16-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 34: World 16-Year Perspective for Online Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Tablet & Capsules Form by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Tablet & Capsules Form by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 37: World 16-Year Perspective for Tablet & Capsules Form by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 38: World Recent Past, Current & Future Analysis for Liquids Form by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 39: World Historic Review for Liquids Form by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 40: World 16-Year Perspective for Liquids Form by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 41: World Recent Past, Current & Future Analysis for Other Dosage Forms by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 42: World Historic Review for Other Dosage Forms by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 43: World 16-Year Perspective for Other Dosage Forms by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Antacids Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
  • TABLE 44: USA Recent Past, Current & Future Analysis for Antacids by Drug Class - Proton Pump Inhibitors, H2 Antagonist, Acid Neutralizers, Anti-H.Pyrolic Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 45: USA Historic Review for Antacids by Drug Class - Proton Pump Inhibitors, H2 Antagonist, Acid Neutralizers, Anti-H.Pyrolic Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 46: USA 16-Year Perspective for Antacids by Drug Class - Percentage Breakdown of Value Sales for Proton Pump Inhibitors, H2 Antagonist, Acid Neutralizers, Anti-H.Pyrolic Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 47: USA Recent Past, Current & Future Analysis for Antacids by Route Of Administration - Injectables Administration and Oral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 48: USA Historic Review for Antacids by Route Of Administration - Injectables Administration and Oral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 49: USA 16-Year Perspective for Antacids by Route Of Administration - Percentage Breakdown of Value Sales for Injectables Administration and Oral Administration for the Years 2014, 2024 & 2030
  • TABLE 50: USA Recent Past, Current & Future Analysis for Antacids by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 51: USA Historic Review for Antacids by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 52: USA 16-Year Perspective for Antacids by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • TABLE 53: USA Recent Past, Current & Future Analysis for Antacids by Dosage Form - Tablet & Capsules Form, Liquids Form and Other Dosage Forms - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 54: USA Historic Review for Antacids by Dosage Form - Tablet & Capsules Form, Liquids Form and Other Dosage Forms Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 55: USA 16-Year Perspective for Antacids by Dosage Form - Percentage Breakdown of Value Sales for Tablet & Capsules Form, Liquids Form and Other Dosage Forms for the Years 2014, 2024 & 2030
• CANADA
  • TABLE 56: Canada Recent Past, Current & Future Analysis for Antacids by Drug Class - Proton Pump Inhibitors, H2 Antagonist, Acid Neutralizers, Anti-H.Pyrolic Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 57: Canada Historic Review for Antacids by Drug Class - Proton Pump Inhibitors, H2 Antagonist, Acid Neutralizers, Anti-H.Pyrolic Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 58: Canada 16-Year Perspective for Antacids by Drug Class - Percentage Breakdown of Value Sales for Proton Pump Inhibitors, H2 Antagonist, Acid Neutralizers, Anti-H.Pyrolic Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 59: Canada Recent Past, Current & Future Analysis for Antacids by Route Of Administration - Injectables Administration and Oral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 60: Canada Historic Review for Antacids by Route Of Administration - Injectables Administration and Oral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 61: Canada 16-Year Perspective for Antacids by Route Of Administration - Percentage Breakdown of Value Sales for Injectables Administration and Oral Administration for the Years 2014, 2024 & 2030
  • TABLE 62: Canada Recent Past, Current & Future Analysis for Antacids by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 63: Canada Historic Review for Antacids by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 64: Canada 16-Year Perspective for Antacids by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • TABLE 65: Canada Recent Past, Current & Future Analysis for Antacids by Dosage Form - Tablet & Capsules Form, Liquids Form and Other Dosage Forms - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 66: Canada Historic Review for Antacids by Dosage Form - Tablet & Capsules Form, Liquids Form and Other Dosage Forms Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 67: Canada 16-Year Perspective for Antacids by Dosage Form - Percentage Breakdown of Value Sales for Tablet & Capsules Form, Liquids Form and Other Dosage Forms for the Years 2014, 2024 & 2030
• JAPAN
  • Antacids Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
  • TABLE 68: Japan Recent Past, Current & Future Analysis for Antacids by Drug Class - Proton Pump Inhibitors, H2 Antagonist, Acid Neutralizers, Anti-H.Pyrolic Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 69: Japan Historic Review for Antacids by Drug Class - Proton Pump Inhibitors, H2 Antagonist, Acid Neutralizers, Anti-H.Pyrolic Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 70: Japan 16-Year Perspective for Antacids by Drug Class - Percentage Breakdown of Value Sales for Proton Pump Inhibitors, H2 Antagonist, Acid Neutralizers, Anti-H.Pyrolic Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 71: Japan Recent Past, Current & Future Analysis for Antacids by Route Of Administration - Injectables Administration and Oral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 72: Japan Historic Review for Antacids by Route Of Administration - Injectables Administration and Oral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 73: Japan 16-Year Perspective for Antacids by Route Of Administration - Percentage Breakdown of Value Sales for Injectables Administration and Oral Administration for the Years 2014, 2024 & 2030
  • TABLE 74: Japan Recent Past, Current & Future Analysis for Antacids by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 75: Japan Historic Review for Antacids by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 76: Japan 16-Year Perspective for Antacids by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • TABLE 77: Japan Recent Past, Current & Future Analysis for Antacids by Dosage Form - Tablet & Capsules Form, Liquids Form and Other Dosage Forms - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 78: Japan Historic Review for Antacids by Dosage Form - Tablet & Capsules Form, Liquids Form and Other Dosage Forms Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 79: Japan 16-Year Perspective for Antacids by Dosage Form - Percentage Breakdown of Value Sales for Tablet & Capsules Form, Liquids Form and Other Dosage Forms for the Years 2014, 2024 & 2030
• CHINA
  • Antacids Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
  • TABLE 80: China Recent Past, Current & Future Analysis for Antacids by Drug Class - Proton Pump Inhibitors, H2 Antagonist, Acid Neutralizers, Anti-H.Pyrolic Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 81: China Historic Review for Antacids by Drug Class - Proton Pump Inhibitors, H2 Antagonist, Acid Neutralizers, Anti-H.Pyrolic Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 82: China 16-Year Perspective for Antacids by Drug Class - Percentage Breakdown of Value Sales for Proton Pump Inhibitors, H2 Antagonist, Acid Neutralizers, Anti-H.Pyrolic Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 83: China Recent Past, Current & Future Analysis for Antacids by Route Of Administration - Injectables Administration and Oral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 84: China Historic Review for Antacids by Route Of Administration - Injectables Administration and Oral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 85: China 16-Year Perspective for Antacids by Route Of Administration - Percentage Breakdown of Value Sales for Injectables Administration and Oral Administration for the Years 2014, 2024 & 2030
  • TABLE 86: China Recent Past, Current & Future Analysis for Antacids by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 87: China Historic Review for Antacids by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 88: China 16-Year Perspective for Antacids by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • TABLE 89: China Recent Past, Current & Future Analysis for Antacids by Dosage Form - Tablet & Capsules Form, Liquids Form and Other Dosage Forms - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 90: China Historic Review for Antacids by Dosage Form - Tablet & Capsules Form, Liquids Form and Other Dosage Forms Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 91: China 16-Year Perspective for Antacids by Dosage Form - Percentage Breakdown of Value Sales for Tablet & Capsules Form, Liquids Form and Other Dosage Forms for the Years 2014, 2024 & 2030
• EUROPE
  • Antacids Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
  • TABLE 92: Europe Recent Past, Current & Future Analysis for Antacids by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 93: Europe Historic Review for Antacids by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 94: Europe 16-Year Perspective for Antacids by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
  • TABLE 95: Europe Recent Past, Current & Future Analysis for Antacids by Drug Class - Proton Pump Inhibitors, H2 Antagonist, Acid Neutralizers, Anti-H.Pyrolic Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 96: Europe Historic Review for Antacids by Drug Class - Proton Pump Inhibitors, H2 Antagonist, Acid Neutralizers, Anti-H.Pyrolic Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 97: Europe 16-Year Perspective for Antacids by Drug Class - Percentage Breakdown of Value Sales for Proton Pump Inhibitors, H2 Antagonist, Acid Neutralizers, Anti-H.Pyrolic Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 98: Europe Recent Past, Current & Future Analysis for Antacids by Route Of Administration - Injectables Administration and Oral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 99: Europe Historic Review for Antacids by Route Of Administration - Injectables Administration and Oral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 100: Europe 16-Year Perspective for Antacids by Route Of Administration - Percentage Breakdown of Value Sales for Injectables Administration and Oral Administration for the Years 2014, 2024 & 2030
  • TABLE 101: Europe Recent Past, Current & Future Analysis for Antacids by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 102: Europe Historic Review for Antacids by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 103: Europe 16-Year Perspective for Antacids by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • TABLE 104: Europe Recent Past, Current & Future Analysis for Antacids by Dosage Form - Tablet & Capsules Form, Liquids Form and Other Dosage Forms - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 105: Europe Historic Review for Antacids by Dosage Form - Tablet & Capsules Form, Liquids Form and Other Dosage Forms Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 106: Europe 16-Year Perspective for Antacids by Dosage Form - Percentage Breakdown of Value Sales for Tablet & Capsules Form, Liquids Form and Other Dosage Forms for the Years 2014, 2024 & 2030
• FRANCE
  • Antacids Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
  • TABLE 107: France Recent Past, Current & Future Analysis for Antacids by Drug Class - Proton Pump Inhibitors, H2 Antagonist, Acid Neutralizers, Anti-H.Pyrolic Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 108: France Historic Review for Antacids by Drug Class - Proton Pump Inhibitors, H2 Antagonist, Acid Neutralizers, Anti-H.Pyrolic Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 109: France 16-Year Perspective for Antacids by Drug Class - Percentage Breakdown of Value Sales for Proton Pump Inhibitors, H2 Antagonist, Acid Neutralizers, Anti-H.Pyrolic Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 110: France Recent Past, Current & Future Analysis for Antacids by Route Of Administration - Injectables Administration and Oral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 111: France Historic Review for Antacids by Route Of Administration - Injectables Administration and Oral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 112: France 16-Year Perspective for Antacids by Route Of Administration - Percentage Breakdown of Value Sales for Injectables Administration and Oral Administration for the Years 2014, 2024 & 2030
  • TABLE 113: France Recent Past, Current & Future Analysis for Antacids by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 114: France Historic Review for Antacids by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 115: France 16-Year Perspective for Antacids by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • TABLE 116: France Recent Past, Current & Future Analysis for Antacids by Dosage Form - Tablet & Capsules Form, Liquids Form and Other Dosage Forms - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 117: France Historic Review for Antacids by Dosage Form - Tablet & Capsules Form, Liquids Form and Other Dosage Forms Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 118: France 16-Year Perspective for Antacids by Dosage Form - Percentage Breakdown of Value Sales for Tablet & Capsules Form, Liquids Form and Other Dosage Forms for the Years 2014, 2024 & 2030
• GERMANY
  • Antacids Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
  • TABLE 119: Germany Recent Past, Current & Future Analysis for Antacids by Drug Class - Proton Pump Inhibitors, H2 Antagonist, Acid Neutralizers, Anti-H.Pyrolic Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 120: Germany Historic Review for Antacids by Drug Class - Proton Pump Inhibitors, H2 Antagonist, Acid Neutralizers, Anti-H.Pyrolic Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 121: Germany 16-Year Perspective for Antacids by Drug Class - Percentage Breakdown of Value Sales for Proton Pump Inhibitors, H2 Antagonist, Acid Neutralizers, Anti-H.Pyrolic Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 122: Germany Recent Past, Current & Future Analysis for Antacids by Route Of Administration - Injectables Administration and Oral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 123: Germany Historic Review for Antacids by Route Of Administration - Injectables Administration and Oral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 124: Germany 16-Year Perspective for Antacids by Route Of Administration - Percentage Breakdown of Value Sales for Injectables Administration and Oral Administration for the Years 2014, 2024 & 2030
  • TABLE 125: Germany Recent Past, Current & Future Analysis for Antacids by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 126: Germany Historic Review for Antacids by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 127: Germany 16-Year Perspective for Antacids by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • TABLE 128: Germany Recent Past, Current & Future Analysis for Antacids by Dosage Form - Tablet & Capsules Form, Liquids Form and Other Dosage Forms - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 129: Germany Historic Review for Antacids by Dosage Form - Tablet & Capsules Form, Liquids Form and Other Dosage Forms Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 130: Germany 16-Year Perspective for Antacids by Dosage Form - Percentage Breakdown of Value Sales for Tablet & Capsules Form, Liquids Form and Other Dosage Forms for the Years 2014, 2024 & 2030
• ITALY
  • TABLE 131: Italy Recent Past, Current & Future Analysis for Antacids by Drug Class - Proton Pump Inhibitors, H2 Antagonist, Acid Neutralizers, Anti-H.Pyrolic Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 132: Italy Historic Review for Antacids by Drug Class - Proton Pump Inhibitors, H2 Antagonist, Acid Neutralizers, Anti-H.Pyrolic Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 133: Italy 16-Year Perspective for Antacids by Drug Class - Percentage Breakdown of Value Sales for Proton Pump Inhibitors, H2 Antagonist, Acid Neutralizers, Anti-H.Pyrolic Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 134: Italy Recent Past, Current & Future Analysis for Antacids by Route Of Administration - Injectables Administration and Oral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 135: Italy Historic Review for Antacids by Route Of Administration - Injectables Administration and Oral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 136: Italy 16-Year Perspective for Antacids by Route Of Administration - Percentage Breakdown of Value Sales for Injectables Administration and Oral Administration for the Years 2014, 2024 & 2030
  • TABLE 137: Italy Recent Past, Current & Future Analysis for Antacids by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 138: Italy Historic Review for Antacids by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 139: Italy 16-Year Perspective for Antacids by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • TABLE 140: Italy Recent Past, Current & Future Analysis for Antacids by Dosage Form - Tablet & Capsules Form, Liquids Form and Other Dosage Forms - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 141: Italy Historic Review for Antacids by Dosage Form - Tablet & Capsules Form, Liquids Form and Other Dosage Forms Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 142: Italy 16-Year Perspective for Antacids by Dosage Form - Percentage Breakdown of Value Sales for Tablet & Capsules Form, Liquids Form and Other Dosage Forms for the Years 2014, 2024 & 2030
• UNITED KINGDOM
  • Antacids Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
  • TABLE 143: UK Recent Past, Current & Future Analysis for Antacids by Drug Class - Proton Pump Inhibitors, H2 Antagonist, Acid Neutralizers, Anti-H.Pyrolic Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 144: UK Historic Review for Antacids by Drug Class - Proton Pump Inhibitors, H2 Antagonist, Acid Neutralizers, Anti-H.Pyrolic Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 145: UK 16-Year Perspective for Antacids by Drug Class - Percentage Breakdown of Value Sales for Proton Pump Inhibitors, H2 Antagonist, Acid Neutralizers, Anti-H.Pyrolic Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 146: UK Recent Past, Current & Future Analysis for Antacids by Route Of Administration - Injectables Administration and Oral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 147: UK Historic Review for Antacids by Route Of Administration - Injectables Administration and Oral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 148: UK 16-Year Perspective for Antacids by Route Of Administration - Percentage Breakdown of Value Sales for Injectables Administration and Oral Administration for the Years 2014, 2024 & 2030
  • TABLE 149: UK Recent Past, Current & Future Analysis for Antacids by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 150: UK Historic Review for Antacids by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 151: UK 16-Year Perspective for Antacids by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • TABLE 152: UK Recent Past, Current & Future Analysis for Antacids by Dosage Form - Tablet & Capsules Form, Liquids Form and Other Dosage Forms - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 153: UK Historic Review for Antacids by Dosage Form - Tablet & Capsules Form, Liquids Form and Other Dosage Forms Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 154: UK 16-Year Perspective for Antacids by Dosage Form - Percentage Breakdown of Value Sales for Tablet & Capsules Form, Liquids Form and Other Dosage Forms for the Years 2014, 2024 & 2030
• SPAIN
  • TABLE 155: Spain Recent Past, Current & Future Analysis for Antacids by Drug Class - Proton Pump Inhibitors, H2 Antagonist, Acid Neutralizers, Anti-H.Pyrolic Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 156: Spain Historic Review for Antacids by Drug Class - Proton Pump Inhibitors, H2 Antagonist, Acid Neutralizers, Anti-H.Pyrolic Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 157: Spain 16-Year Perspective for Antacids by Drug Class - Percentage Breakdown of Value Sales for Proton Pump Inhibitors, H2 Antagonist, Acid Neutralizers, Anti-H.Pyrolic Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 158: Spain Recent Past, Current & Future Analysis for Antacids by Route Of Administration - Injectables Administration and Oral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 159: Spain Historic Review for Antacids by Route Of Administration - Injectables Administration and Oral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 160: Spain 16-Year Perspective for Antacids by Route Of Administration - Percentage Breakdown of Value Sales for Injectables Administration and Oral Administration for the Years 2014, 2024 & 2030
  • TABLE 161: Spain Recent Past, Current & Future Analysis for Antacids by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 162: Spain Historic Review for Antacids by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 163: Spain 16-Year Perspective for Antacids by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • TABLE 164: Spain Recent Past, Current & Future Analysis for Antacids by Dosage Form - Tablet & Capsules Form, Liquids Form and Other Dosage Forms - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 165: Spain Historic Review for Antacids by Dosage Form - Tablet & Capsules Form, Liquids Form and Other Dosage Forms Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 166: Spain 16-Year Perspective for Antacids by Dosage Form - Percentage Breakdown of Value Sales for Tablet & Capsules Form, Liquids Form and Other Dosage Forms for the Years 2014, 2024 & 2030
• RUSSIA
  • TABLE 167: Russia Recent Past, Current & Future Analysis for Antacids by Drug Class - Proton Pump Inhibitors, H2 Antagonist, Acid Neutralizers, Anti-H.Pyrolic Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 168: Russia Historic Review for Antacids by Drug Class - Proton Pump Inhibitors, H2 Antagonist, Acid Neutralizers, Anti-H.Pyrolic Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 169: Russia 16-Year Perspective for Antacids by Drug Class - Percentage Breakdown of Value Sales for Proton Pump Inhibitors, H2 Antagonist, Acid Neutralizers, Anti-H.Pyrolic Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 170: Russia Recent Past, Current & Future Analysis for Antacids by Route Of Administration - Injectables Administration and Oral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 171: Russia Historic Review for Antacids by Route Of Administration - Injectables Administration and Oral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 172: Russia 16-Year Perspective for Antacids by Route Of Administration - Percentage Breakdown of Value Sales for Injectables Administration and Oral Administration for the Years 2014, 2024 & 2030
  • TABLE 173: Russia Recent Past, Current & Future Analysis for Antacids by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 174: Russia Historic Review for Antacids by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 175: Russia 16-Year Perspective for Antacids by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • TABLE 176: Russia Recent Past, Current & Future Analysis for Antacids by Dosage Form - Tablet & Capsules Form, Liquids Form and Other Dosage Forms - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 177: Russia Historic Review for Antacids by Dosage Form - Tablet & Capsules Form, Liquids Form and Other Dosage Forms Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 178: Russia 16-Year Perspective for Antacids by Dosage Form - Percentage Breakdown of Value Sales for Tablet & Capsules Form, Liquids Form and Other Dosage Forms for the Years 2014, 2024 & 2030
• REST OF EUROPE
  • TABLE 179: Rest of Europe Recent Past, Current & Future Analysis for Antacids by Drug Class - Proton Pump Inhibitors, H2 Antagonist, Acid Neutralizers, Anti-H.Pyrolic Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 180: Rest of Europe Historic Review for Antacids by Drug Class - Proton Pump Inhibitors, H2 Antagonist, Acid Neutralizers, Anti-H.Pyrolic Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 181: Rest of Europe 16-Year Perspective for Antacids by Drug Class - Percentage Breakdown of Value Sales for Proton Pump Inhibitors, H2 Antagonist, Acid Neutralizers, Anti-H.Pyrolic Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 182: Rest of Europe Recent Past, Current & Future Analysis for Antacids by Route Of Administration - Injectables Administration and Oral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 183: Rest of Europe Historic Review for Antacids by Route Of Administration - Injectables Administration and Oral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 184: Rest of Europe 16-Year Perspective for Antacids by Route Of Administration - Percentage Breakdown of Value Sales for Injectables Administration and Oral Administration for the Years 2014, 2024 & 2030
  • TABLE 185: Rest of Europe Recent Past, Current & Future Analysis for Antacids by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 186: Rest of Europe Historic Review for Antacids by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 187: Rest of Europe 16-Year Perspective for Antacids by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • TABLE 188: Rest of Europe Recent Past, Current & Future Analysis for Antacids by Dosage Form - Tablet & Capsules Form, Liquids Form and Other Dosage Forms - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 189: Rest of Europe Historic Review for Antacids by Dosage Form - Tablet & Capsules Form, Liquids Form and Other Dosage Forms Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 190: Rest of Europe 16-Year Perspective for Antacids by Dosage Form - Percentage Breakdown of Value Sales for Tablet & Capsules Form, Liquids Form and Other Dosage Forms for the Years 2014, 2024 & 2030
• ASIA-PACIFIC
  • Antacids Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
  • TABLE 191: Asia-Pacific Recent Past, Current & Future Analysis for Antacids by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 192: Asia-Pacific Historic Review for Antacids by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 193: Asia-Pacific 16-Year Perspective for Antacids by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
  • TABLE 194: Asia-Pacific Recent Past, Current & Future Analysis for Antacids by Drug Class - Proton Pump Inhibitors, H2 Antagonist, Acid Neutralizers, Anti-H.Pyrolic Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 195: Asia-Pacific Historic Review for Antacids by Drug Class - Proton Pump Inhibitors, H2 Antagonist, Acid Neutralizers, Anti-H.Pyrolic Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 196: Asia-Pacific 16-Year Perspective for Antacids by Drug Class - Percentage Breakdown of Value Sales for Proton Pump Inhibitors, H2 Antagonist, Acid Neutralizers, Anti-H.Pyrolic Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 197: Asia-Pacific Recent Past, Current & Future Analysis for Antacids by Route Of Administration - Injectables Administration and Oral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 198: Asia-Pacific Historic Review for Antacids by Route Of Administration - Injectables Administration and Oral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 199: Asia-Pacific 16-Year Perspective for Antacids by Route Of Administration - Percentage Breakdown of Value Sales for Injectables Administration and Oral Administration for the Years 2014, 2024 & 2030
  • TABLE 200: Asia-Pacific Recent Past, Current & Future Analysis for Antacids by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 201: Asia-Pacific Historic Review for Antacids by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 202: Asia-Pacific 16-Year Perspective for Antacids by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • TABLE 203: Asia-Pacific Recent Past, Current & Future Analysis for Antacids by Dosage Form - Tablet & Capsules Form, Liquids Form and Other Dosage Forms - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 204: Asia-Pacific Historic Review for Antacids by Dosage Form - Tablet & Capsules Form, Liquids Form and Other Dosage Forms Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 205: Asia-Pacific 16-Year Perspective for Antacids by Dosage Form - Percentage Breakdown of Value Sales for Tablet & Capsules Form, Liquids Form and Other Dosage Forms for the Years 2014, 2024 & 2030
• AUSTRALIA
  • Antacids Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
  • TABLE 206: Australia Recent Past, Current & Future Analysis for Antacids by Drug Class - Proton Pump Inhibitors, H2 Antagonist, Acid Neutralizers, Anti-H.Pyrolic Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 207: Australia Historic Review for Antacids by Drug Class - Proton Pump Inhibitors, H2 Antagonist, Acid Neutralizers, Anti-H.Pyrolic Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 208: Australia 16-Year Perspective for Antacids by Drug Class - Percentage Breakdown of Value Sales for Proton Pump Inhibitors, H2 Antagonist, Acid Neutralizers, Anti-H.Pyrolic Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 209: Australia Recent Past, Current & Future Analysis for Antacids by Route Of Administration - Injectables Administration and Oral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 210: Australia Historic Review for Antacids by Route Of Administration - Injectables Administration and Oral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 211: Australia 16-Year Perspective for Antacids by Route Of Administration - Percentage Breakdown of Value Sales for Injectables Administration and Oral Administration for the Years 2014, 2024 & 2030
  • TABLE 212: Australia Recent Past, Current & Future Analysis for Antacids by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 213: Australia Historic Review for Antacids by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 214: Australia 16-Year Perspective for Antacids by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • TABLE 215: Australia Recent Past, Current & Future Analysis for Antacids by Dosage Form - Tablet & Capsules Form, Liquids Form and Other Dosage Forms - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 216: Australia Historic Review for Antacids by Dosage Form - Tablet & Capsules Form, Liquids Form and Other Dosage Forms Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 217: Australia 16-Year Perspective for Antacids by Dosage Form - Percentage Breakdown of Value Sales for Tablet & Capsules Form, Liquids Form and Other Dosage Forms for the Years 2014, 2024 & 2030
• INDIA
  • Antacids Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
  • TABLE 218: India Recent Past, Current & Future Analysis for Antacids by Drug Class - Proton Pump Inhibitors, H2 Antagonist, Acid Neutralizers, Anti-H.Pyrolic Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 219: India Historic Review for Antacids by Drug Class - Proton Pump Inhibitors, H2 Antagonist, Acid Neutralizers, Anti-H.Pyrolic Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 220: India 16-Year Perspective for Antacids by Drug Class - Percentage Breakdown of Value Sales for Proton Pump Inhibitors, H2 Antagonist, Acid Neutralizers, Anti-H.Pyrolic Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 221: India Recent Past, Current & Future Analysis for Antacids by Route Of Administration - Injectables Administration and Oral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 222: India Historic Review for Antacids by Route Of Administration - Injectables Administration and Oral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 223: India 16-Year Perspective for Antacids by Route Of Administration - Percentage Breakdown of Value Sales for Injectables Administration and Oral Administration for the Years 2014, 2024 & 2030
  • TABLE 224: India Recent Past, Current & Future Analysis for Antacids by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 225: India Historic Review for Antacids by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 226: India 16-Year Perspective for Antacids by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • TABLE 227: India Recent Past, Current & Future Analysis for Antacids by Dosage Form - Tablet & Capsules Form, Liquids Form and Other Dosage Forms - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 228: India Historic Review for Antacids by Dosage Form - Tablet & Capsules Form, Liquids Form and Other Dosage Forms Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 229: India 16-Year Perspective for Antacids by Dosage Form - Percentage Breakdown of Value Sales for Tablet & Capsules Form, Liquids Form and Other Dosage Forms for the Years 2014, 2024 & 2030
• SOUTH KOREA
  • TABLE 230: South Korea Recent Past, Current & Future Analysis for Antacids by Drug Class - Proton Pump Inhibitors, H2 Antagonist, Acid Neutralizers, Anti-H.Pyrolic Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 231: South Korea Historic Review for Antacids by Drug Class - Proton Pump Inhibitors, H2 Antagonist, Acid Neutralizers, Anti-H.Pyrolic Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 232: South Korea 16-Year Perspective for Antacids by Drug Class - Percentage Breakdown of Value Sales for Proton Pump Inhibitors, H2 Antagonist, Acid Neutralizers, Anti-H.Pyrolic Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 233: South Korea Recent Past, Current & Future Analysis for Antacids by Route Of Administration - Injectables Administration and Oral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 234: South Korea Historic Review for Antacids by Route Of Administration - Injectables Administration and Oral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 235: South Korea 16-Year Perspective for Antacids by Route Of Administration - Percentage Breakdown of Value Sales for Injectables Administration and Oral Administration for the Years 2014, 2024 & 2030
  • TABLE 236: South Korea Recent Past, Current & Future Analysis for Antacids by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 237: South Korea Historic Review for Antacids by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 238: South Korea 16-Year Perspective for Antacids by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • TABLE 239: South Korea Recent Past, Current & Future Analysis for Antacids by Dosage Form - Tablet & Capsules Form, Liquids Form and Other Dosage Forms - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 240: South Korea Historic Review for Antacids by Dosage Form - Tablet & Capsules Form, Liquids Form and Other Dosage Forms Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 241: South Korea 16-Year Perspective for Antacids by Dosage Form - Percentage Breakdown of Value Sales for Tablet & Capsules Form, Liquids Form and Other Dosage Forms for the Years 2014, 2024 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 242: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Antacids by Drug Class - Proton Pump Inhibitors, H2 Antagonist, Acid Neutralizers, Anti-H.Pyrolic Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 243: Rest of Asia-Pacific Historic Review for Antacids by Drug Class - Proton Pump Inhibitors, H2 Antagonist, Acid Neutralizers, Anti-H.Pyrolic Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 244: Rest of Asia-Pacific 16-Year Perspective for Antacids by Drug Class - Percentage Breakdown of Value Sales for Proton Pump Inhibitors, H2 Antagonist, Acid Neutralizers, Anti-H.Pyrolic Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 245: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Antacids by Route Of Administration - Injectables Administration and Oral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 246: Rest of Asia-Pacific Historic Review for Antacids by Route Of Administration - Injectables Administration and Oral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 247: Rest of Asia-Pacific 16-Year Perspective for Antacids by Route Of Administration - Percentage Breakdown of Value Sales for Injectables Administration and Oral Administration for the Years 2014, 2024 & 2030
  • TABLE 248: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Antacids by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 249: Rest of Asia-Pacific Historic Review for Antacids by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 250: Rest of Asia-Pacific 16-Year Perspective for Antacids by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • TABLE 251: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Antacids by Dosage Form - Tablet & Capsules Form, Liquids Form and Other Dosage Forms - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 252: Rest of Asia-Pacific Historic Review for Antacids by Dosage Form - Tablet & Capsules Form, Liquids Form and Other Dosage Forms Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 253: Rest of Asia-Pacific 16-Year Perspective for Antacids by Dosage Form - Percentage Breakdown of Value Sales for Tablet & Capsules Form, Liquids Form and Other Dosage Forms for the Years 2014, 2024 & 2030
• LATIN AMERICA
  • Antacids Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
  • TABLE 254: Latin America Recent Past, Current & Future Analysis for Antacids by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 255: Latin America Historic Review for Antacids by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 256: Latin America 16-Year Perspective for Antacids by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
  • TABLE 257: Latin America Recent Past, Current & Future Analysis for Antacids by Drug Class - Proton Pump Inhibitors, H2 Antagonist, Acid Neutralizers, Anti-H.Pyrolic Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 258: Latin America Historic Review for Antacids by Drug Class - Proton Pump Inhibitors, H2 Antagonist, Acid Neutralizers, Anti-H.Pyrolic Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 259: Latin America 16-Year Perspective for Antacids by Drug Class - Percentage Breakdown of Value Sales for Proton Pump Inhibitors, H2 Antagonist, Acid Neutralizers, Anti-H.Pyrolic Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 260: Latin America Recent Past, Current & Future Analysis for Antacids by Route Of Administration - Injectables Administration and Oral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 261: Latin America Historic Review for Antacids by Route Of Administration - Injectables Administration and Oral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 262: Latin America 16-Year Perspective for Antacids by Route Of Administration - Percentage Breakdown of Value Sales for Injectables Administration and Oral Administration for the Years 2014, 2024 & 2030
  • TABLE 263: Latin America Recent Past, Current & Future Analysis for Antacids by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 264: Latin America Historic Review for Antacids by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 265: Latin America 16-Year Perspective for Antacids by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • TABLE 266: Latin America Recent Past, Current & Future Analysis for Antacids by Dosage Form - Tablet & Capsules Form, Liquids Form and Other Dosage Forms - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 267: Latin America Historic Review for Antacids by Dosage Form - Tablet & Capsules Form, Liquids Form and Other Dosage Forms Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 268: Latin America 16-Year Perspective for Antacids by Dosage Form - Percentage Breakdown of Value Sales for Tablet & Capsules Form, Liquids Form and Other Dosage Forms for the Years 2014, 2024 & 2030
• ARGENTINA
  • TABLE 269: Argentina Recent Past, Current & Future Analysis for Antacids by Drug Class - Proton Pump Inhibitors, H2 Antagonist, Acid Neutralizers, Anti-H.Pyrolic Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 270: Argentina Historic Review for Antacids by Drug Class - Proton Pump Inhibitors, H2 Antagonist, Acid Neutralizers, Anti-H.Pyrolic Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 271: Argentina 16-Year Perspective for Antacids by Drug Class - Percentage Breakdown of Value Sales for Proton Pump Inhibitors, H2 Antagonist, Acid Neutralizers, Anti-H.Pyrolic Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 272: Argentina Recent Past, Current & Future Analysis for Antacids by Route Of Administration - Injectables Administration and Oral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 273: Argentina Historic Review for Antacids by Route Of Administration - Injectables Administration and Oral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 274: Argentina 16-Year Perspective for Antacids by Route Of Administration - Percentage Breakdown of Value Sales for Injectables Administration and Oral Administration for the Years 2014, 2024 & 2030
  • TABLE 275: Argentina Recent Past, Current & Future Analysis for Antacids by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 276: Argentina Historic Review for Antacids by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 277: Argentina 16-Year Perspective for Antacids by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • TABLE 278: Argentina Recent Past, Current & Future Analysis for Antacids by Dosage Form - Tablet & Capsules Form, Liquids Form and Other Dosage Forms - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 279: Argentina Historic Review for Antacids by Dosage Form - Tablet & Capsules Form, Liquids Form and Other Dosage Forms Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 280: Argentina 16-Year Perspective for Antacids by Dosage Form - Percentage Breakdown of Value Sales for Tablet & Capsules Form, Liquids Form and Other Dosage Forms for the Years 2014, 2024 & 2030
• BRAZIL
  • TABLE 281: Brazil Recent Past, Current & Future Analysis for Antacids by Drug Class - Proton Pump Inhibitors, H2 Antagonist, Acid Neutralizers, Anti-H.Pyrolic Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 282: Brazil Historic Review for Antacids by Drug Class - Proton Pump Inhibitors, H2 Antagonist, Acid Neutralizers, Anti-H.Pyrolic Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 283: Brazil 16-Year Perspective for Antacids by Drug Class - Percentage Breakdown of Value Sales for Proton Pump Inhibitors, H2 Antagonist, Acid Neutralizers, Anti-H.Pyrolic Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 284: Brazil Recent Past, Current & Future Analysis for Antacids by Route Of Administration - Injectables Administration and Oral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 285: Brazil Historic Review for Antacids by Route Of Administration - Injectables Administration and Oral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 286: Brazil 16-Year Perspective for Antacids by Route Of Administration - Percentage Breakdown of Value Sales for Injectables Administration and Oral Administration for the Years 2014, 2024 & 2030
  • TABLE 287: Brazil Recent Past, Current & Future Analysis for Antacids by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 288: Brazil Historic Review for Antacids by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 289: Brazil 16-Year Perspective for Antacids by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • TABLE 290: Brazil Recent Past, Current & Future Analysis for Antacids by Dosage Form - Tablet & Capsules Form, Liquids Form and Other Dosage Forms - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 291: Brazil Historic Review for Antacids by Dosage Form - Tablet & Capsules Form, Liquids Form and Other Dosage Forms Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 292: Brazil 16-Year Perspective for Antacids by Dosage Form - Percentage Breakdown of Value Sales for Tablet & Capsules Form, Liquids Form and Other Dosage Forms for the Years 2014, 2024 & 2030
• MEXICO
  • TABLE 293: Mexico Recent Past, Current & Future Analysis for Antacids by Drug Class - Proton Pump Inhibitors, H2 Antagonist, Acid Neutralizers, Anti-H.Pyrolic Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 294: Mexico Historic Review for Antacids by Drug Class - Proton Pump Inhibitors, H2 Antagonist, Acid Neutralizers, Anti-H.Pyrolic Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 295: Mexico 16-Year Perspective for Antacids by Drug Class - Percentage Breakdown of Value Sales for Proton Pump Inhibitors, H2 Antagonist, Acid Neutralizers, Anti-H.Pyrolic Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 296: Mexico Recent Past, Current & Future Analysis for Antacids by Route Of Administration - Injectables Administration and Oral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 297: Mexico Historic Review for Antacids by Route Of Administration - Injectables Administration and Oral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 298: Mexico 16-Year Perspective for Antacids by Route Of Administration - Percentage Breakdown of Value Sales for Injectables Administration and Oral Administration for the Years 2014, 2024 & 2030
  • TABLE 299: Mexico Recent Past, Current & Future Analysis for Antacids by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 300: Mexico Historic Review for Antacids by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 301: Mexico 16-Year Perspective for Antacids by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • TABLE 302: Mexico Recent Past, Current & Future Analysis for Antacids by Dosage Form - Tablet & Capsules Form, Liquids Form and Other Dosage Forms - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 303: Mexico Historic Review for Antacids by Dosage Form - Tablet & Capsules Form, Liquids Form and Other Dosage Forms Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 304: Mexico 16-Year Perspective for Antacids by Dosage Form - Percentage Breakdown of Value Sales for Tablet & Capsules Form, Liquids Form and Other Dosage Forms for the Years 2014, 2024 & 2030
• REST OF LATIN AMERICA
  • TABLE 305: Rest of Latin America Recent Past, Current & Future Analysis for Antacids by Drug Class - Proton Pump Inhibitors, H2 Antagonist, Acid Neutralizers, Anti-H.Pyrolic Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 306: Rest of Latin America Historic Review for Antacids by Drug Class - Proton Pump Inhibitors, H2 Antagonist, Acid Neutralizers, Anti-H.Pyrolic Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 307: Rest of Latin America 16-Year Perspective for Antacids by Drug Class - Percentage Breakdown of Value Sales for Proton Pump Inhibitors, H2 Antagonist, Acid Neutralizers, Anti-H.Pyrolic Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 308: Rest of Latin America Recent Past, Current & Future Analysis for Antacids by Route Of Administration - Injectables Administration and Oral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 309: Rest of Latin America Historic Review for Antacids by Route Of Administration - Injectables Administration and Oral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 310: Rest of Latin America 16-Year Perspective for Antacids by Route Of Administration - Percentage Breakdown of Value Sales for Injectables Administration and Oral Administration for the Years 2014, 2024 & 2030
  • TABLE 311: Rest of Latin America Recent Past, Current & Future Analysis for Antacids by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 312: Rest of Latin America Historic Review for Antacids by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 313: Rest of Latin America 16-Year Perspective for Antacids by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • TABLE 314: Rest of Latin America Recent Past, Current & Future Analysis for Antacids by Dosage Form - Tablet & Capsules Form, Liquids Form and Other Dosage Forms - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 315: Rest of Latin America Historic Review for Antacids by Dosage Form - Tablet & Capsules Form, Liquids Form and Other Dosage Forms Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 316: Rest of Latin America 16-Year Perspective for Antacids by Dosage Form - Percentage Breakdown of Value Sales for Tablet & Capsules Form, Liquids Form and Other Dosage Forms for the Years 2014, 2024 & 2030
• MIDDLE EAST
  • Antacids Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
  • TABLE 317: Middle East Recent Past, Current & Future Analysis for Antacids by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 318: Middle East Historic Review for Antacids by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 319: Middle East 16-Year Perspective for Antacids by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
  • TABLE 320: Middle East Recent Past, Current & Future Analysis for Antacids by Drug Class - Proton Pump Inhibitors, H2 Antagonist, Acid Neutralizers, Anti-H.Pyrolic Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 321: Middle East Historic Review for Antacids by Drug Class - Proton Pump Inhibitors, H2 Antagonist, Acid Neutralizers, Anti-H.Pyrolic Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 322: Middle East 16-Year Perspective for Antacids by Drug Class - Percentage Breakdown of Value Sales for Proton Pump Inhibitors, H2 Antagonist, Acid Neutralizers, Anti-H.Pyrolic Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 323: Middle East Recent Past, Current & Future Analysis for Antacids by Route Of Administration - Injectables Administration and Oral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 324: Middle East Historic Review for Antacids by Route Of Administration - Injectables Administration and Oral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 325: Middle East 16-Year Perspective for Antacids by Route Of Administration - Percentage Breakdown of Value Sales for Injectables Administration and Oral Administration for the Years 2014, 2024 & 2030
  • TABLE 326: Middle East Recent Past, Current & Future Analysis for Antacids by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 327: Middle East Historic Review for Antacids by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 328: Middle East 16-Year Perspective for Antacids by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • TABLE 329: Middle East Recent Past, Current & Future Analysis for Antacids by Dosage Form - Tablet & Capsules Form, Liquids Form and Other Dosage Forms - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 330: Middle East Historic Review for Antacids by Dosage Form - Tablet & Capsules Form, Liquids Form and Other Dosage Forms Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 331: Middle East 16-Year Perspective for Antacids by Dosage Form - Percentage Breakdown of Value Sales for Tablet & Capsules Form, Liquids Form and Other Dosage Forms for the Years 2014, 2024 & 2030
• IRAN
  • TABLE 332: Iran Recent Past, Current & Future Analysis for Antacids by Drug Class - Proton Pump Inhibitors, H2 Antagonist, Acid Neutralizers, Anti-H.Pyrolic Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 333: Iran Historic Review for Antacids by Drug Class - Proton Pump Inhibitors, H2 Antagonist, Acid Neutralizers, Anti-H.Pyrolic Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 334: Iran 16-Year Perspective for Antacids by Drug Class - Percentage Breakdown of Value Sales for Proton Pump Inhibitors, H2 Antagonist, Acid Neutralizers, Anti-H.Pyrolic Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 335: Iran Recent Past, Current & Future Analysis for Antacids by Route Of Administration - Injectables Administration and Oral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 336: Iran Historic Review for Antacids by Route Of Administration - Injectables Administration and Oral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 337: Iran 16-Year Perspective for Antacids by Route Of Administration - Percentage Breakdown of Value Sales for Injectables Administration and Oral Administration for the Years 2014, 2024 & 2030
  • TABLE 338: Iran Recent Past, Current & Future Analysis for Antacids by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 339: Iran Historic Review for Antacids by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 340: Iran 16-Year Perspective for Antacids by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • TABLE 341: Iran Recent Past, Current & Future Analysis for Antacids by Dosage Form - Tablet & Capsules Form, Liquids Form and Other Dosage Forms - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 342: Iran Historic Review for Antacids by Dosage Form - Tablet & Capsules Form, Liquids Form and Other Dosage Forms Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 343: Iran 16-Year Perspective for Antacids by Dosage Form - Percentage Breakdown of Value Sales for Tablet & Capsules Form, Liquids Form and Other Dosage Forms for the Years 2014, 2024 & 2030
• ISRAEL
  • TABLE 344: Israel Recent Past, Current & Future Analysis for Antacids by Drug Class - Proton Pump Inhibitors, H2 Antagonist, Acid Neutralizers, Anti-H.Pyrolic Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 345: Israel Historic Review for Antacids by Drug Class - Proton Pump Inhibitors, H2 Antagonist, Acid Neutralizers, Anti-H.Pyrolic Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 346: Israel 16-Year Perspective for Antacids by Drug Class - Percentage Breakdown of Value Sales for Proton Pump Inhibitors, H2 Antagonist, Acid Neutralizers, Anti-H.Pyrolic Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 347: Israel Recent Past, Current & Future Analysis for Antacids by Route Of Administration - Injectables Administration and Oral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 348: Israel Historic Review for Antacids by Route Of Administration - Injectables Administration and Oral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 349: Israel 16-Year Perspective for Antacids by Route Of Administration - Percentage Breakdown of Value Sales for Injectables Administration and Oral Administration for the Years 2014, 2024 & 2030
  • TABLE 350: Israel Recent Past, Current & Future Analysis for Antacids by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 351: Israel Historic Review for Antacids by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 352: Israel 16-Year Perspective for Antacids by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • TABLE 353: Israel Recent Past, Current & Future Analysis for Antacids by Dosage Form - Tablet & Capsules Form, Liquids Form and Other Dosage Forms - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 354: Israel Historic Review for Antacids by Dosage Form - Tablet & Capsules Form, Liquids Form and Other Dosage Forms Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 355: Israel 16-Year Perspective for Antacids by Dosage Form - Percentage Breakdown of Value Sales for Tablet & Capsules Form, Liquids Form and Other Dosage Forms for the Years 2014, 2024 & 2030
• SAUDI ARABIA
  • TABLE 356: Saudi Arabia Recent Past, Current & Future Analysis for Antacids by Drug Class - Proton Pump Inhibitors, H2 Antagonist, Acid Neutralizers, Anti-H.Pyrolic Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 357: Saudi Arabia Historic Review for Antacids by Drug Class - Proton Pump Inhibitors, H2 Antagonist, Acid Neutralizers, Anti-H.Pyrolic Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 358: Saudi Arabia 16-Year Perspective for Antacids by Drug Class - Percentage Breakdown of Value Sales for Proton Pump Inhibitors, H2 Antagonist, Acid Neutralizers, Anti-H.Pyrolic Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 359: Saudi Arabia Recent Past, Current & Future Analysis for Antacids by Route Of Administration - Injectables Administration and Oral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 360: Saudi Arabia Historic Review for Antacids by Route Of Administration - Injectables Administration and Oral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 361: Saudi Arabia 16-Year Perspective for Antacids by Route Of Administration - Percentage Breakdown of Value Sales for Injectables Administration and Oral Administration for the Years 2014, 2024 & 2030
  • TABLE 362: Saudi Arabia Recent Past, Current & Future Analysis for Antacids by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 363: Saudi Arabia Historic Review for Antacids by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 364: Saudi Arabia 16-Year Perspective for Antacids by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • TABLE 365: Saudi Arabia Recent Past, Current & Future Analysis for Antacids by Dosage Form - Tablet & Capsules Form, Liquids Form and Other Dosage Forms - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 366: Saudi Arabia Historic Review for Antacids by Dosage Form - Tablet & Capsules Form, Liquids Form and Other Dosage Forms Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 367: Saudi Arabia 16-Year Perspective for Antacids by Dosage Form - Percentage Breakdown of Value Sales for Tablet & Capsules Form, Liquids Form and Other Dosage Forms for the Years 2014, 2024 & 2030
• UNITED ARAB EMIRATES
  • TABLE 368: UAE Recent Past, Current & Future Analysis for Antacids by Drug Class - Proton Pump Inhibitors, H2 Antagonist, Acid Neutralizers, Anti-H.Pyrolic Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 369: UAE Historic Review for Antacids by Drug Class - Proton Pump Inhibitors, H2 Antagonist, Acid Neutralizers, Anti-H.Pyrolic Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 370: UAE 16-Year Perspective for Antacids by Drug Class - Percentage Breakdown of Value Sales for Proton Pump Inhibitors, H2 Antagonist, Acid Neutralizers, Anti-H.Pyrolic Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 371: UAE Recent Past, Current & Future Analysis for Antacids by Route Of Administration - Injectables Administration and Oral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 372: UAE Historic Review for Antacids by Route Of Administration - Injectables Administration and Oral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 373: UAE 16-Year Perspective for Antacids by Route Of Administration - Percentage Breakdown of Value Sales for Injectables Administration and Oral Administration for the Years 2014, 2024 & 2030
  • TABLE 374: UAE Recent Past, Current & Future Analysis for Antacids by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 375: UAE Historic Review for Antacids by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 376: UAE 16-Year Perspective for Antacids by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • TABLE 377: UAE Recent Past, Current & Future Analysis for Antacids by Dosage Form - Tablet & Capsules Form, Liquids Form and Other Dosage Forms - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 378: UAE Historic Review for Antacids by Dosage Form - Tablet & Capsules Form, Liquids Form and Other Dosage Forms Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 379: UAE 16-Year Perspective for Antacids by Dosage Form - Percentage Breakdown of Value Sales for Tablet & Capsules Form, Liquids Form and Other Dosage Forms for the Years 2014, 2024 & 2030
• REST OF MIDDLE EAST
  • TABLE 380: Rest of Middle East Recent Past, Current & Future Analysis for Antacids by Drug Class - Proton Pump Inhibitors, H2 Antagonist, Acid Neutralizers, Anti-H.Pyrolic Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 381: Rest of Middle East Historic Review for Antacids by Drug Class - Proton Pump Inhibitors, H2 Antagonist, Acid Neutralizers, Anti-H.Pyrolic Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 382: Rest of Middle East 16-Year Perspective for Antacids by Drug Class - Percentage Breakdown of Value Sales for Proton Pump Inhibitors, H2 Antagonist, Acid Neutralizers, Anti-H.Pyrolic Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 383: Rest of Middle East Recent Past, Current & Future Analysis for Antacids by Route Of Administration - Injectables Administration and Oral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 384: Rest of Middle East Historic Review for Antacids by Route Of Administration - Injectables Administration and Oral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 385: Rest of Middle East 16-Year Perspective for Antacids by Route Of Administration - Percentage Breakdown of Value Sales for Injectables Administration and Oral Administration for the Years 2014, 2024 & 2030
  • TABLE 386: Rest of Middle East Recent Past, Current & Future Analysis for Antacids by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 387: Rest of Middle East Historic Review for Antacids by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 388: Rest of Middle East 16-Year Perspective for Antacids by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • TABLE 389: Rest of Middle East Recent Past, Current & Future Analysis for Antacids by Dosage Form - Tablet & Capsules Form, Liquids Form and Other Dosage Forms - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 390: Rest of Middle East Historic Review for Antacids by Dosage Form - Tablet & Capsules Form, Liquids Form and Other Dosage Forms Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 391: Rest of Middle East 16-Year Perspective for Antacids by Dosage Form - Percentage Breakdown of Value Sales for Tablet & Capsules Form, Liquids Form and Other Dosage Forms for the Years 2014, 2024 & 2030
• AFRICA
  • Antacids Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
  • TABLE 392: Africa Recent Past, Current & Future Analysis for Antacids by Drug Class - Proton Pump Inhibitors, H2 Antagonist, Acid Neutralizers, Anti-H.Pyrolic Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 393: Africa Historic Review for Antacids by Drug Class - Proton Pump Inhibitors, H2 Antagonist, Acid Neutralizers, Anti-H.Pyrolic Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 394: Africa 16-Year Perspective for Antacids by Drug Class - Percentage Breakdown of Value Sales for Proton Pump Inhibitors, H2 Antagonist, Acid Neutralizers, Anti-H.Pyrolic Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 395: Africa Recent Past, Current & Future Analysis for Antacids by Route Of Administration - Injectables Administration and Oral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 396: Africa Historic Review for Antacids by Route Of Administration - Injectables Administration and Oral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 397: Africa 16-Year Perspective for Antacids by Route Of Administration - Percentage Breakdown of Value Sales for Injectables Administration and Oral Administration for the Years 2014, 2024 & 2030
  • TABLE 398: Africa Recent Past, Current & Future Analysis for Antacids by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 399: Africa Historic Review for Antacids by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 400: Africa 16-Year Perspective for Antacids by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • TABLE 401: Africa Recent Past, Current & Future Analysis for Antacids by Dosage Form - Tablet & Capsules Form, Liquids Form and Other Dosage Forms - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 402: Africa Historic Review for Antacids by Dosage Form - Tablet & Capsules Form, Liquids Form and Other Dosage Forms Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 403: Africa 16-Year Perspective for Antacids by Dosage Form - Percentage Breakdown of Value Sales for Tablet & Capsules Form, Liquids Form and Other Dosage Forms for the Years 2014, 2024 & 2030

IV. COMPETITION